Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Lemborexant (LEM), a dual-orexin-receptor-antagonist, was evaluated in this study of Korean participants with insomnia disorder. Study E2006-J082-204 (Study 204), a 1-month, multicenter, double-blind, placebo (PBO)-controlled, parallel-group study, evaluated LEM 5 mg (LEM5) or LEM 10 mg (LEM10) in participants aged 19–80 years with insomnia disorder (sleep efficiency [SE] ≤ 85%; latency to persistent sleep [LPS] ≥ 30 min).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
